In vitro experiments, Omaveloxolone, as an agonist of Nrf2, attenuates the destruction of Nrf2, thereby rescuing the FRDA cell model (Abeti et al., 2018). The gene discussed is NFE2L2; the disease is Friedreich ataxia.